Newswise — New research from North Carolina State University shows that platelet microparticles are an effective way to deliver therapeutic drugs directly to the heart following a heart attack. This method increases drug concentration at the site and could help heart attack patients reduce side effects from drugs used to aid recovery.
The damage from a heart attack doesn’t stop when the initial event ends. Following a heart attack, inflammatory cells release a protein called Interleukin-1β (IL-1β), which induces an inflammatory response and promotes scarring on the heart over time. IL-1β blocking drugs have shown promise in phase three clinical trials, but they have significant risks and side effects.
“IL-1β seems like the bad guy here, but it is one of the body’s defenses against any outside pathogen – it induces inflammation as a way to kill those invading agents,” says Ke Cheng, Randall B. Terry Jr. Distinguished Professor in Regenerative Medicine at NC State and professor in the NC State/UNC-Chapel Hill Joint Department of Biomedical Engineering.
“So if you create a drug that blocks IL-1β function and deliver it intravenously throughout the patient’s body, you could create more problems than you solve. But if you could somehow target the drug to the heart, it might reduce the risk of side effects and give the patient the therapy they need.”
Platelets – the tiny blood cells that promote blood clotting – have a natural “homing” ability that allow them to locate the site of heart attack damage. Cheng and his colleagues previously demonstrated it was possible to take advantage of this ability by placing platelet membranes on stem cells and nanoparticles for the targeted repair of injured hearts.
In this new work, the team armed platelet-derived microparticles with an IL-1β blocking antibody (the same one tested in the clinical trials) and tested it in a mouse model. Drug concentration in the hearts of mice who received the targeted therapy was about 10 times higher than in those without targeted therapy. Additionally, mice receiving the targeted drug therapy recovered 50% of cardiac function after 70 days, compared to 25% recovery in mice who received the traditional (untargeted) drug application.
“The platelets are effectively giving the drug a piggyback ride directly to the site of the heart attack, delivering a higher concentration where it is needed,” Cheng says. “Hopefully this method will allow doctors to use less of the drug while obtaining the same benefits, and reduce side effects at the same time.”
The work appears in Science Advances and is supported by the National Institutes of Health and the American Heart Association. Cheng is corresponding author. Postdoctoral research fellow Zhenhua Li is first author.
Note to editors: An abstract follows.
“Targeted Anti-IL-1β Platelet Microparticles for Cardiac Detoxing and Repair”
Authors: Zhenhua Li, Shiqi Hu, Ke Huang, Teng Su, Jhon Cores and Ke Cheng, Department of Molecular Biomedical Sciences North Carolina State University and Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina – Chapel Hill
Published: Feb. 5 in Science Advances
An acute myocardial infarction (AMI) induces a sterile inflammatory response that facilitates further heart injury and promotes adverse cardiac remodeling. Interleukin (IL)-1β plays a central role in the sterile inflammatory response that results from AMI. Thus, IL-1β blockage is a promising strategy for treatment of AMI. However, conventional IL-1β blockers lack targeting specificity. This increases the risk of serious side effects. To address this problem herein, we fabricated platelet microparticles (PMs) armed with anti-IL-1β antibodies to neutralize IL-1β after AMI and to prevent adverse cardiac remodeling. Our results indicate that the infarct-targeting PMs could bind to the injured heart, increasing the number of anti-IL-1β antibodies therein. The anti-IL-1β platelet microparticles (IL1-PMs) protect the cardiomyocytes from apoptosis by neutralizing IL-1β and decreasing IL-1β-driven caspase-3 activity. Our findings indicate that IL1-PM is a promising cardiac detoxification agent that removes cytotoxic IL-1β during AMI and induces therapeutic cardiac repair.